Exelixis presented Phase 3 data showing its oral TKI zanzalintinib in combination with Roche’s Tecentriq reduced the risk of death by 20% versus the standard comparator in previously treated metastatic colorectal cancer. Median overall survival was 10.9 months for the zanzalintinib‑Tecentriq arm versus 9.4 months for the control arm at median follow‑up. The result represents the first demonstration of a TKI improving outcomes when paired with a checkpoint inhibitor in this patient population, according to Exelixis. The company acknowledged a higher grade 3–4 adverse event rate (59% vs. 37%) and is positioning zanzalintinib as a potential new franchise molecule following Cabometyx, pending regulatory reviews and further analyses.